Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
about
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisNail Psoriasis: A Review of Treatment OptionsBiologic agents in juvenile spondyloarthropathiesSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Treatment challenges in axial spondylarthritis and future directions.Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Certolizumab pegol in axial spondyloarthritis.Adalimumab in the treatment of immune-mediated diseases.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.A Review of Psoriasis, Therapies, and Suicide.Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Efficacy and safety of adalimumab in ankylosing spondylitis.New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease.Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature reviewEfficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis.Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment.
P2860
Q24603648-BB30CF22-E2C2-4077-839D-A445C9996FB0Q26753038-A5B1AC55-0F26-4B64-A59D-26799A9F746EQ26766263-9C58D581-7011-4C10-8052-412852704A2EQ30612910-0656C08E-F379-4F84-B5F5-77E20DCFD368Q36715135-C707F290-8992-4C54-961C-FEB8746BA6FBQ37352347-32823499-8788-401E-BB33-73DF0DFDE23FQ37873493-859E6B4E-01C7-479B-91AD-8139F6C098FFQ38124281-10A6B49B-6DC0-4DA2-810E-DA910DFDDA2FQ38127746-36AB3D83-8937-46F4-AD7E-2E85E737BB30Q38145501-CF1486B6-F8A2-492F-8111-552F8BC5F1B2Q38161555-5110E1B7-EAC6-48F3-8B9E-5BDD729CA9E4Q38207760-6B113EA3-B7FF-44A4-B7F9-A00DEEB4DDE8Q38630548-96CEFAE1-5357-4726-AEB0-B9A1939490F6Q38840271-C895EA48-79AE-4F0E-AC70-AB2EC26E37D2Q38978414-07A01284-19DB-4E95-844D-50712CBB5521Q38993324-5F05A018-EE78-4EF3-B335-FE31E26BE567Q39373505-C08C05BB-1DE3-4120-9DB2-8D11503FE4A2Q42701796-87C22CC4-F058-4DD4-A711-00837F8FA032Q43115288-373F22ED-4B3C-433D-8E0E-CD4E24197098Q45229094-3F5EB385-33C4-42A9-B594-19FD823EFC6BQ47114261-9C00BFD8-C4F7-4715-AF7C-40D1AF3A0CD6Q52874129-7F7F7272-CFFE-48BA-A651-4FB19BEFCD11Q53063681-032B5C64-CC69-4C83-A3A7-BB5859D95AFE
P2860
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@ast
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@en
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@nl
type
label
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@ast
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@en
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@nl
prefLabel
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@ast
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@en
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@nl
P2093
P2860
P356
P1476
Effectiveness and safety of ad ...... tumor necrosis factor therapy.
@en
P2093
Filip Van den Bosch
Hartmut Kupper
Martin Rudwaleit
Martina Kron
Sonja Kary
P2860
P2888
P356
10.1186/AR3054
P577
2010-06-16T00:00:00Z
P5875
P6179
1007925506